Equities
Health CareMedical Equipment and Services
  • Price (USD)325.58
  • Today's Change1.89 / 0.58%
  • Shares traded159.59k
  • 1 Year change+6.34%
  • Beta0.9038
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform3
Hold3
Sell0
Strong Sell0

Share price forecast in USD

The 6 analysts offering 12 month price targets for Bio Rad Laboratories Inc have a median target of 395.00, with a high estimate of 469.00 and a low estimate of 315.00. The median estimate represents a 22.03% increase from the last price of 323.69.
High44.1%469.00
Med21.3%395.00
Low-3.2%315.00

Earnings history & estimates in USD

On Oct 30, 2024, Bio Rad Laboratories Inc reported 3rd quarter 2024 earnings of 2.01 per share. This result exceeded the 1.16 consensus of the 6 analysts covering the company and under-performed last year's 3rd quarter results by 13.73%.
The next earnings announcement is expected on Feb 13, 2025.
Average growth rate+1.84%
Bio Rad Laboratories Inc reported annual 2023 earnings of 11.78 per share on Feb 15, 2024.
Average growth rate+17.91%
More ▼

Revenue history & estimates in USD

Bio-Rad Laboratories, Inc. had 3rd quarter 2024 revenues of 649.73m. This bettered the 628.17m consensus of the 6 analysts covering the company. This was 4.01% below the prior year's 3rd quarter results.
Average growth rate+0.93%
Bio-Rad Laboratories, Inc. had revenues for the full year 2023 of 2.67bn. This was 4.67% below the prior year's results.
Average growth rate+4.03%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.